Notably, both miR‐19a‐3p overexpression and TGF‐β antibody antagonism may serve as promising therapeutic strategies to reverse CD4+ T cell suppression and ameliorated the prognosis of HBV‐related DLBCL. This evidence concerns the gene CD4 and diffuse large B-cell lymphoma.